NCT04929509

Brief Summary

Background: Great efforts have been undertaken for dental caries prevention. Among the recent remineralizing materials, Nano silver fluoride varnish products which are based on nanotechnology have been proposed for "repairing" enamel . Regenerative medicine-based approaches for caries treatment focus on biomimetic remineralization of initial carious lesions as a minimal invasive therapy using Self-Assembling Peptide P11-4 (Curodont Repair) which enhances remineralization of white spot lesions. Purpose of the Study: The aim of this study is to compare clinically and microbiologically the therapeutic effect of Self Assembling Peptide P11-4 (Curodont Repair), nano silver fluoride varnish and 5% fluoride varnish (Duraflor) on remineralization of enamel White Spot Lesions in permanent teeth of adults.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 5, 2020

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 15, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 18, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 5, 2021

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2022

Completed
Last Updated

June 18, 2021

Status Verified

June 1, 2021

Enrollment Period

10 months

First QC Date

June 15, 2021

Last Update Submit

June 15, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in the activity status of lesions scored using ICDAS-LAA

    Change in the activity status of lesions scored using ICDAS-LAA from baseline to final follow up.

    12 months

Secondary Outcomes (2)

  • Change in mean DIAGNOdent readings.

    12 months

  • Microbial count of mutans streptococci, lactobacilli.

    6 months

Study Arms (3)

self-assembling peptide (P11-4)

EXPERIMENTAL

Curodont Repair; Credentis will be applied to the white spot lesion at baseline.

Other: self-assembling peptide

nanosilver fluoride varnish

ACTIVE COMPARATOR

(Study group) Nano-silver fluoride varnish will be applied to the white spot lesion at baseline.

Other: nanosilver fluoride varnish

sodium fluoride varnish

PLACEBO COMPARATOR

(Control group) Fluoride varnish (Duraflor) will be applied to the white spot lesion at baseline and 6 months follow up.

Other: sodium fluoride varnish

Interventions

each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators

Also known as: Curodont repair
self-assembling peptide (P11-4)

The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.

nanosilver fluoride varnish

5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.

Also known as: duraflor
sodium fluoride varnish

Eligibility Criteria

Age10 Years - 24 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • An age range of 10-24 years ( age of young adolescents and youth as described by the WHO was selected (WHO, 2019). 2. The presence of at least one visible WSL in the buccal surface of permanent teeth with ICDAS II score of 1, or 2. 3. Completion of an informed consent to participate in the study

You may not qualify if:

  • \. Patients receiving the following medications: tetracyclines, any other medication known to stain teeth or any medication causing dry mouth and/or limiting salivary flow. 2. Patients receiving any antibiotic within 1 month prior to each saliva sample collection 3. Selected tooth with microcavities or dentinal involvement due to loss of enamel tissues. 4. Selected tooth with a restoration adjacent to the lesions to avoid false- positive readings. 5. Selected tooth with fluoride application \< 3 months prior to study treatment. 6. Selected tooth with discolouration, enamel hypoplasia or fluorosis. 7. Patients with multiple cavitations to avoid variability in microbiological analysis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of dentistry

Alexandria, Egypt

RECRUITING

Related Publications (2)

  • Atteya SM, Amer HA, Saleh SM, Safwat Y. The effect of nano silver fluoride, self-assembling peptide and sodium fluoride varnish on salivary cariogenic bacteria: a randomized controlled clinical trial. Clin Oral Investig. 2024 Feb 23;28(3):167. doi: 10.1007/s00784-024-05562-0.

  • Atteya SM, Amer HA, Saleh SM, Safwat Y. Self-assembling peptide and nano-silver fluoride in remineralizing early enamel carious lesions: randomized controlled clinical trial. BMC Oral Health. 2023 Aug 19;23(1):577. doi: 10.1186/s12903-023-03269-4.

MeSH Terms

Interventions

Bifluorid 12Duraflor

Study Officials

  • Hala A Amer, PHD

    Alexandria University

    STUDY DIRECTOR
  • Susan M Saleh, PHD

    Alexandria University

    PRINCIPAL INVESTIGATOR
  • Yara S Selim, PHD

    Alexandria University

    PRINCIPAL INVESTIGATOR
  • Sara M Atteya, PHD

    Alexandria University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

June 15, 2021

First Posted

June 18, 2021

Study Start

December 5, 2020

Primary Completion

October 5, 2021

Study Completion

January 1, 2022

Last Updated

June 18, 2021

Record last verified: 2021-06

Locations